|
|
||||||||||
|
J Am Coll Cardiol, 2006; 48:2432-2439, doi:10.1016/j.jacc.2006.08.033
(Published online 28 November 2006). © 2006 by the American College of Cardiology Foundation |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||



* Department of Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
GangNeung, Korea
Cardiovascular Research Foundation, New York, New York
Washington Hospital Center, Washington, DC.
Manuscript received April 14, 2006; revised manuscript received August 1, 2006, accepted August 7, 2006.
* Reprint requests and correspondence: Dr. Seung-Jung Park, Departments of Medicine, University of Ulsan College of Medicine, Cardiac Center, Asan Medical Center, 388-1 Poongnap-dong, Songpa-gu, Seoul 138-736, Korea. (Email: sjpark{at}amc.seoul.kr).
OBJECTIVES: This study used serial angiographic and intravascular ultrasound (IVUS) analysis to evaluate the long-term efficacy of a nonpolymeric, paclitaxel-eluting stent coating on intimal hyperplasia (IH) 2 years after implantation.
BACKGROUND: Long-term efficacy of patients treated with nonpolymeric paclitaxel-eluting stents beyond 1 year has not been well determined.
METHODS: Patients were randomized to placebo or 1 of 2 doses of paclitaxel (low dose, 1.28 µg/mm2; high dose, 3.10 µg/mm2). Complete after-procedure, 6-month, and 2-year angiographic and IVUS data were available in 53 patients (17, 17, and 19 patients, respectively).
RESULTS: Baseline characteristics were similar among the 3 groups. Although 6-month minimal luminal diameter (MLD) was significantly smaller in placebo compared with paclitaxel-eluting stent patients (1.9 ± 0.6 mm in placebo, 2.5 ± 0.6 mm in low-dose, and 2.6 ± 0.5 mm in high-dose patients, p = 0.004), the MLDs at 2 years were similar (2.3 ± 0.6 mm, 2.3 ± 0.7 mm, and 2.0 ± 0.8 mm, respectively, p = 0.4). Despite a stepwise reduction in IH accumulation at 6 months (23 ± 18 mm3 in placebo, 14 ± 11 mm3 in low-dose, and 10 ± 12 mm3 in high-dose, p = 0.017), the increase of IH volume from 6 months to 2 years was significantly greater in the high-dose patients (13 ± 14 mm3 in high-dose vs. 4 ± 7 mm3 in low-dose patients, p = 0.074; and vs. 1 ± 13 mm3 in placebo, p = 0.019). Late target lesion revascularization (beyond 1 year) was performed in 2 high-dose patients.
CONCLUSIONS: Despite the suppression of IH after non-polymeric paclitaxel-eluting stents compared with bare-metal stents at 6 months, a "late catch-up" IH growth was found in the high-dose patients at 2-year follow-up.
| |||||||||
This article has been cited by other articles:
![]() |
R. Wessely, A. Kastrati, J. Mehilli, A. Dibra, J. Pache, and A. Schomig Randomized trial of rapamycin- and paclitaxel-eluting stents with identical biodegradable polymeric coating and design Eur. Heart J., November 2, 2007; 28(22): 2720 - 2725. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Adriaenssens, J. Mehilli, R. Wessely, G. Ndrepepa, M. Seyfarth, A. Wieczorek, B. Blaich, R. Iijima, J. Pache, A. Kastrati, et al. Does Addition of Estradiol Improve the Efficacy of a Rapamycin-Eluting Stent?: Results of the ISAR-PEACE Randomized Trial J. Am. Coll. Cardiol., March 27, 2007; 49(12): 1265 - 1271. [Abstract] [Full Text] [PDF] |
||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |